Quris is developing a fully automated, self-training AI platform designed to better predict clinical safety and efficacy for new drug candidates.
The company is pioneering clinical trials on chips, which involves testing thousands of novel drug candidates on hundreds of stem-cells-derived “patients-on-a-chip”. Its fully automated, self-training AI platform is designed to accurately predict clinical safety and efficacy for novel drugs faster and more cost effectively than before – all while minimizing animal testing.
The Quris platform is being trained on known safe and toxic drugs, so it can then rapidly screen thousands of potential new drug formulations.
The company’s initial focus is on rare genetic diseases that can’t be modelled in animals. The first drug developed on the platform addresses Fragile-X Syndrome, a common inherited cause of autism. Quris’s Fragile-X drug is preparing for clinical testing in early 2022.
Dual-headquartered in Boston and Israel, the company recently made its public launch, along with the closing of a $9M seed round of funding. Quris is led by an experienced team, including Moderna co-founder Robert Langer, and Nobel Laureate Aaron Ciechanover.
Subscribe for alerts on new companies featured on Startups.Bio
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …